By rray, 12 July, 2024 If pt chooses pharmacotherapy offer monotherapy w antimuscarinic or 3 agonist or combo tx w an blocker an antimuscarinic or 3 agonist CR B nbsp nbsp If OAB predominant LUTS Assess relative contribution of BOO secondary to BPH Evaluate presence and severit
By rray, 12 July, 2024 In the context of shared decision making clinicians may offer noninvasive therapies pharmacotherapy or minimally invasive therapies EO nbsp nbsp If OAB predominant LUTS bladder outlet reduction surgeries e g transurethral resection HoLEP or photovaporizat
By rray, 12 July, 2024 Discontinue oral meds if appropriate response to minimally invasive procedure but restart if efficacy not maintained EO nbsp nbsp If good tx response There s likely no added benefit to continuing OAB meds are assoc w polypharmacy added cost and potential
By rray, 12 July, 2024 Offer in the context of shared decision making trials of behavioral noninvasive or pharmacological mgmt not required EO
By rray, 12 July, 2024 May offer to pts unable unwilling to undergo behavioral noninvasive or pharmacological therapies CP nbsp nbsp If inadequate response to behavioral tx or medication mgmt PTNS implantable tibial nerve stimulation BTX and SNM assoc w high success rates durab
